Acadia Pharmaceuticals buy Royal Bank of Canada
Start price
28.02.24
/
50%
€22.00
Target price
28.02.25
€32.29
Performance (%)
-36.25%
Price
03.06.24
€14.03
Summary
This prediction is currently active. The BUY prediction by Royal_Bank_of_Canada for Acadia Pharmaceuticals is performing very badly with a performance of -36.25%. This prediction currently runs until 28.02.25. The prediction end date can be changed by Royal_Bank_of_Canada at any time. Royal_Bank_of_Canada has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m |
---|---|---|
Acadia Pharmaceuticals | 3.582% | 3.582% |
iShares Core DAX® | 0.805% | 2.118% |
iShares Nasdaq 100 | 1.995% | 4.071% |
iShares Nikkei 225® | 1.264% | -2.374% |
iShares S&P 500 | 1.637% | 2.287% |
Comments by Royal_Bank_of_Canada for this prediction
In the thread Acadia Pharmaceuticals diskutieren
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its price target lowered by analysts at Royal Bank of Canada from $36.00 to $35.00. They now have an "outperform" rating on the stock.
Ratings data for ACAD provided by MarketBeat
Stopped prediction by Royal_Bank_of_Canada for Acadia Pharmaceuticals
Acadia Pharmaceuticals
Start price
Target price
Perf. (%)
€22.60
03.11.23
03.11.23
€30.73
03.11.24
03.11.24
-37.94%
03.06.24
03.06.24
Acadia Pharmaceuticals
Start price
Target price
Perf. (%)
€29.00
14.07.23
14.07.23
€29.37
14.07.24
14.07.24
-51.64%
03.06.24
03.06.24